Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 2
2012 3
2013 3
2014 1
2016 3
2017 1
2018 2
2019 1
2020 2
2021 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. Kjeldsen JW, et al. Among authors: hendel hw. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. Nat Med. 2021. PMID: 34887574 Free PMC article. Clinical Trial.
Automated synthesis of 68 Ga/177 Lu-PSMA on the Trasis miniAllinOne.
Sørensen MA, Andersen VL, Hendel HW, Vriamont C, Warnier C, Masset J, Huynh THV. Sørensen MA, et al. Among authors: hendel hw. J Labelled Comp Radiopharm. 2020 Jun 30;63(8):393-403. doi: 10.1002/jlcr.3846. Epub 2020 Jun 1. J Labelled Comp Radiopharm. 2020. PMID: 32374450
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. Kjeldsen JW, et al. Among authors: hendel hw. Nat Med. 2022 Apr;28(4):871. doi: 10.1038/s41591-022-01771-w. Nat Med. 2022. PMID: 35260843 Free PMC article. No abstract available.
Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol.
Spindler NJ, Persson GF, Theile S, Nielsen DL, Høgdall EV, Al-Farra G, Hendel HW, Lorentzen T, Svane IM, Lindberg H, Eefsen RL. Spindler NJ, et al. Among authors: hendel hw. BMJ Open. 2023 Jan 30;13(1):e063500. doi: 10.1136/bmjopen-2022-063500. BMJ Open. 2023. PMID: 36717150 Free PMC article.
Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression.
Homburg S, Christensen CB, Pedersen M, Sørensen SG, Donia M, Svane IM, Hendel HW, Ellebaek E. Homburg S, et al. Among authors: hendel hw. Cancers (Basel). 2024 Feb 27;16(5):964. doi: 10.3390/cancers16050964. Cancers (Basel). 2024. PMID: 38473325 Free PMC article.
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.
Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, Nøttrup TJ, Andersen P, Hasselager T, Met Ö, Nelson BH, Donia M, Svane IM. Pedersen M, et al. Among authors: hendel hw. Oncoimmunology. 2018 Sep 26;7(12):e1502905. doi: 10.1080/2162402X.2018.1502905. eCollection 2018. Oncoimmunology. 2018. PMID: 30524900 Free PMC article.
26 results